AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.
AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors Read More »
Cybin Inc. today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985, to a deuterated psilocybin analog in the Company’s CYB003 investigational drug program.
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
Cardinal Health reported fourth quarter fiscal year 2023 revenues of $53.5 billion, an increase of 13% from the fourth quarter of last year.
The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company’s shareholders.
Bulletin from Swedish Orphan Biovitrum (Sobi)’s Extraordinary General Meeting (EGM) Read More »
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.
USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc. Read More »
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2023.
SINOVAC Reports Unaudited First Half of 2023 Financial Results Read More »
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, reported its unaudited financial results for the three and six months ended June 30, 2023.
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights Read More »
Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.
Asieris Pharmaceuticals announced that the Government of Hong Kong Special Administrative Region Department of Health has approved the registration applications for the Uro-G and Uro-V disposable cystoscopic system.
